Literature DB >> 12555009

Untreatable pain resulting from abdominal cancer: new hope from biophysics?

Giuseppe Marineo1.   

Abstract

CONTEXT: Visceral pain characterizing pancreatic cancer is the most difficult symptom of the disease to control and can significantly impair the quality of life which remains and increase the demand for euthanasia. AIM: To investigate a possible new method based on biophysical principles (scrambler therapy) to be used in the effective treatment of drug-resistant oncological pain of the visceral/neuropathic type.
SETTING: Eleven terminal cancer patients (3 pancreas, 4 colon, 4 gastric) suffering from elevated drug resistant visceral pain.
DESIGN: The trial program was related to the first ten treatment sessions. Subsequently, each patient continued to receive treatment until death. MAIN OUTCOME MEASURES: Pain measures were performed using the visual analogue scale before and after each treatment session and accompanied by diary recordings of the duration of analgesia in the hours following each single application. Any variation in pain-killing drug consumption was also recorded.
RESULTS: All patients reacted positively to the treatment throughout the whole reference period. Pain intensity showed a significant decrease (P<0.001), accompanied by a gradual rise both in the pain threshold and the duration of analgesia. Nine (81.8%) of the patients suspended pain-killers within the first 5 applications, while the remaining two (18.2%) considerably reduced the dosage taken prior to scrambler therapy. No undesirable side effects were observed. Compliance was found to be optimal.
CONCLUSIONS: The preliminary results obtained using scrambler therapy are extremely encouraging, both in terms of enhanced pain control after each treatment session and in view of the possible maintenance of effectiveness over time.

Entities:  

Mesh:

Year:  2003        PMID: 12555009

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  26 in total

1.  Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies.

Authors:  Paolo Notaro; Carlo Alberto Dell'Agnola; Alessandro J Dell'Agnola; Alessio Amatu; Katia Bruna Bencardino; Salvatore Siena
Journal:  Support Care Cancer       Date:  2015-09-26       Impact factor: 3.603

2.  Reproducibility of results on chronic pain with MC5-A Calmare® device from independent studies.

Authors:  Marianna Ricci; Sara Pirotti; Emanuela Scarpi; Marco Burgio; Marco Maltoni; Elisabetta Sansoni; Dino Amadori
Journal:  Support Care Cancer       Date:  2011-05-06       Impact factor: 3.603

3.  Inaccuracy in the article "Managing chronic pain: results from an open-label study using MC5-A Calmare device in Support Care Cancer".

Authors:  Giuseppe Marineo
Journal:  Support Care Cancer       Date:  2011-08-02       Impact factor: 3.603

4.  Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial.

Authors:  Charles Loprinzi; Jennifer G Le-Rademacher; Neil Majithia; Ryan P McMurray; Carrie R O'Neill; Markus A Bendel; Andreas Beutler; Daniel H Lachance; Andrea Cheville; David M Strick; David F Black; Jon C Tilburt; Thomas J Smith
Journal:  Support Care Cancer       Date:  2019-06-17       Impact factor: 3.603

5.  Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy.

Authors:  Thomas J Smith; Patrick J Coyne; Gwendolyn L Parker; Patricia Dodson; Viswanathan Ramakrishnan
Journal:  J Pain Symptom Manage       Date:  2010-12       Impact factor: 3.612

6.  Managing chronic pain: results from an open-label study using MC5-A Calmare® device.

Authors:  Marianna Ricci; Sara Pirotti; Emanuela Scarpi; Marco Burgio; Marco Maltoni; Elisabetta Sansoni; Dino Amadori
Journal:  Support Care Cancer       Date:  2011-03-11       Impact factor: 3.603

7.  Clinical experiences on the effect of scrambler therapy for patients with postherpetic neuralgia.

Authors:  Young Kwon Ko; Ho Young Lee; Wang Yong Lee
Journal:  Korean J Pain       Date:  2013-01-04

8.  Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.

Authors:  Deirdre R Pachman; Breanna L Weisbrod; Drew K Seisler; Debra L Barton; Kelliann C Fee-Schroeder; Thomas J Smith; Daniel H Lachance; Heshan Liu; Randy A Shelerud; Andrea L Cheville; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2014-09-24       Impact factor: 3.603

9.  A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy.

Authors:  Patrick J Coyne; Wen Wan; Patricia Dodson; Craig Swainey; Thomas J Smith
Journal:  J Pain Palliat Care Pharmacother       Date:  2013-10-21

Review 10.  Scrambler Therapy for the management of chronic pain.

Authors:  Neil Majithia; Thomas J Smith; Patrick J Coyne; Salahadin Abdi; Deirdre R Pachman; Daniel Lachance; Randy Shelerud; Andrea Cheville; Jeffrey R Basford; David Farley; Carrie O'Neill; Kathryn J Ruddy; Frank Sparadeo; Andreas Beutler; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2016-04-04       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.